Canaccord lowered the firm’s price target on Merit Medical to $102 from $112 and keeps a Buy rating on the shares. The firm noted they posted a Q1 beat but no guidance was issued and with a pathway to continued margin improvement, and potential upside from new products on the horizon, we reiterate their rating.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI: